Organism: Homo sapiens
Gene: 39925_at
Selected probe(set): 213622_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39925_at (213622_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):6.1183176
Number of Samples:2 / 3

Experimental	esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control	esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

Relative Expression (log2-ratio):-4.184952
Number of Samples:3 / 3

Experimental	hepatocyte-like cell differentiation study 1 (15d)
	Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control	hepatocyte-like cell differentiation study 1 (10d)
	Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.

Relative Expression (log2-ratio):-3.9869537
Number of Samples:3 / 3

Experimental	hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
	Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control	hepatocyte-like cell differentiation study 1 (10d)
	Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.

Relative Expression (log2-ratio):3.9515495
Number of Samples:19 / 4

Experimental	Merkel cell carcinoma study 3 (primary)
	Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control	skin squamous cell carcinoma study 6
	Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).

Relative Expression (log2-ratio):3.8153305
Number of Samples:19 / 64

Experimental	Merkel cell carcinoma study 3 (primary)
	Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control	normal skin tissue
	Normal skin samples from healthy donors.

Relative Expression (log2-ratio):-3.7675333
Number of Samples:2 / 3

Experimental	glioma study 17 (small cell glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):3.6702738
Number of Samples:11 / 64

Experimental	Merkel cell carcinoma study 3 (metastatic)
	Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control	normal skin tissue
	Normal skin samples from healthy donors.

Relative Expression (log2-ratio):3.4567242
Number of Samples:15 / 22

Experimental	brain tumor study 1 (pilocytic astrocytoma)
	Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma.
Control	brain tumor study 1 (medulloblastoma)
	Primary tumor tissue sample from the brain of patients with medulloblastoma.

Relative Expression (log2-ratio):3.080391
Number of Samples:2 / 2

Experimental	bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control	bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

Relative Expression (log2-ratio):-3.0506353
Number of Samples:4 / 2

Experimental	skin squamous cell carcinoma study 6
	Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).
Control	basal cell carcinoma study 2
	Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).